Alembic Pharmaceuticals Limited

NSE APLLTD.NS

Alembic Pharmaceuticals Limited Free Cash Flow for the year ending March 31, 2024: USD 57.04 M

Alembic Pharmaceuticals Limited Free Cash Flow is USD 57.04 M for the year ending March 31, 2024, a 67.10% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Alembic Pharmaceuticals Limited Free Cash Flow for the year ending March 31, 2023 was USD 34.13 M, a 104.54% change year over year.
Alembic Pharmaceuticals Limited Free Cash Flow for the year ending March 31, 2022 was USD 16.69 M, a -84.80% change year over year.
Alembic Pharmaceuticals Limited Free Cash Flow for the year ending March 31, 2021 was USD 109.78 M, a 389.50% change year over year.
Alembic Pharmaceuticals Limited Free Cash Flow for the year ending March 31, 2020 was USD -37.92 M, a -653.75% change year over year.

Key data

Date	Free Cash Flow	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities

NSE: APLLTD.NS

Alembic Pharmaceuticals Limited

CEO	Mr. Chirayu Ramanbhai Amin
IPO Date	Sept. 20, 2011
Location	India
Headquarters	Alembic Road
Employees	14,858
Sector	Health Care
Industries Pharmaceuticals

Description

Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. It offers active pharmaceutical ingredients and formulations. The company also provides branded and generic formulations in various therapeutic areas, such as cardiology, gynecology, gastrology, ophthalmology, dermatology, nephrology/urology, orthopedics, anti-infective, cold and cough, and anti-diabetic. In addition, it exports its products. Alembic Pharmaceuticals Limited was founded in 1907 and is headquartered in Vadodara, India.

Key trends

Past 5 years